Nivolumab for carcinoma, transitional cell

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 27 Jul 2016: Trial registered, NCT02845323
  2. 16 May 2017: Trial started, NCT02845323

The trials

NCT02845323: Neoadjuvant Nivolumab With and Without Urelumab in Cisplatin-Ineligible or Chemotherapy-refusing Patients With Muscle-Invasive Urothelial Carcinoma of the Bladder

State
Under way
Phase
Phase 2
People
15 taking part
Started
16 May 2017
Primary completion
31 Jul 2027
Arms
Nivolumab in combination with Urelumab
Results
None posted
  1. 27 Jul 2016: Trial registered
  2. 16 May 2017: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Also known as Nivolumab 3 mg/kg + platinum-based chemotherapy (2 cycles, neoadjuvant), Opdivo, Opdivo qvantig component nivolumab, Opdualag component nivolumab.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.